Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE: JNJ) and its prescription drugs unit are responsible for helping fuel Oklahoma's opioid drug problem, a judge ruled Monday, making the conglomerate the first to be held to blame by a court for the epidemic.

Judge Orders Johnson & Johnson To Pay $572M In Opioid Case

Johnson & Johnson stock jumped Monday after an Oklahoma judge ordered the Dow Jones pharma giant to pay $572 million to help abate the state's opioid epidemic. The state sought $17 billion.

Pharma Giant J&J Must Pay $572 Million For Oklahoman Opioid Crisis

An Oklahoma judge on Monday found Johnson & Johnson  liable for fueling an opioid epidemic in the state by deceptively marketing painkillers, and ordered the drugmaker to pay damages of $572 million.

Oklahoma judge holds J&J liable in opioid epidemic, orders $572 million damages

In landmark case, Oklahoma is first state to sue an opioid manufacturer in court

Johnson & Johnson responsible for fueling opioid crisis in Oklahoma, judge rules

Johnson & Johnson, which was the only defendant in the seven-week trial, has denied any wrongdoing.

Judge rules against Johnson & Johnson in landmark opioid case in Oklahoma

J&J, which marketed the opioid painkillers Duragesic and Nucynta, has denied any wrongdoing.

Watch: Oklahoma judge to issue landmark verdict in Johnson & Johnson $17 billion opioid trial

An Oklahoma judge on Monday will decide whether Johnson & Johnson  should be held liable in a $17 billion lawsuit alleging the drugmaker's marketing practices fueled the opioid epidemic by flooding the market with painkillers.

Oklahoma judge to rule in $17 billion opioid lawsuit against J&J

Johnson & Johnson (NYSE:JNJ) has been facing several lawsuits over its different products, including talc, hip-plants, and the blood thinner, Xarelto. There are a total of around 50,000 such cases against the company.

How Much Will It Cost Johnson & Johnson To Settle Most of Its Lawsuits?

AbbVie

Which stock wins in a battle between these two big pharma companies?

Better Buy:  Johnson & Johnson vs. AbbVie

However, the stock offers limited upside. Shares appear fairly valued relative to peers.

Will Lawsuits Sink Johnson & Johnson Stock?

J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.

J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week

A ruling against J&J could mean more big payouts in similar cases across the country.

Johnson & Johnson opioid trial judge expected to issue landmark verdict Monday

No one is going to confuse Johnson & Johnson stock as a surefire bet in the broader healthcare space. That said, if you can tolerate the risk, JNJ makes a somewhat rational contrarian case.

Johnson & Johnson Stock Is a Gamble, but an Interesting One

Pfizer

UnitedHealth Group

Even though they are prone to headlines during elections, here are 3 healthcare stocks to buy: PFE, UNH and JNJ.
The post 3 Healthcare Stocks to Trade: UNH, JNJ and PFE appeared first on InvestorPlace.

3 Healthcare Stocks to Trade: UNH, JNJ and PFE

NVIDIA

Top Research Reports for Berkshire Hathaway, Johnson & Johnson & NVIDIA

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Why Is Johnson & Johnson (JNJ) Down 1.2% Since Last Earnings Report?

Here's how much income you'll get from Johnson and Johnson stock as compared with bonds or bank accounts in coming years.
The post JNJ Stock Is a Way Better Investment Than Bonds or CDs appeared first on InvestorPlace.

JNJ Stock Is a Way Better Investment Than Bonds or CDs

Bank of America

Cisco Systems

Intel

JPMorgan Chase & Co

Microsoft

Exxon Mobil

These stocks are projected to offer the biggest dividend hikes in 2020, which should bolster their prices in a volatile market, according to Goldman Sachs.

8 Blue Chips Seen Fueled By Major Dividend Growth As Outlook Darkens

Novartis

And the one big pharma most likely to benefit the most.

5 Biggest New Drugs Approved in 2019 So Far

FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.

J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients

Brookfield Renewable Partners

Starbucks

Buy these three companies for a no-stress approach to investing.

3 Stocks You Can Set and Forget: BEP, JNJ & SBUX

Bristol-Myers

Merck

These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Concerns over J&J's baby powder threaten the company's family-friendly image.

Johnson & Johnson says jury ruled in its favor in lawsuit alleging baby powder caused mesothelioma

Arrowhead Pharmaceuticals

World Hepatitis Day inspired Janssen Sciences to reaffirm its commitment to eliminate the threat by 2030.

Arrowhead Pharmaceuticals - Janssen Collaboration Could Be A Game Changer

The Federal Trade Commission in June issued civil subpoenas to Johnson and Johnson  as part of an investigation of whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

News for Johnson & Johnson Stock (JNJ)